Wien (www.aktiencheck.de) - AbbVie-Aktienanalyse der Raiffeisen Bank International AG:
Raphael Schicho, Analyst der Raiffeisen Bank International AG (RBI), nimmt in einer…
AbbVie raises profit forecast as CEO cites business "momentum"…
AbbVie raises 2024 profit forecast on strong sales of key drugs Skyrizi, Rinvoq…
…
Der Pharma-Riese AbbVie verstärkt sich im Bereich der neurologischen Erkrankungen mit der milliardenschweren Übernahme von Aliada Therapeutics. Das Akquisitionsobjekt verfügt…
Der Pharma-Riese AbbVie verstärkt sich im Bereich der neurologischen Erkrankungen mit der milliardenschweren Übernahme von Aliada Therapeutics. Das Akquisitionsobjekt verfügt…
Kulmbach (www.aktiencheck.de) - AbbVie-Aktienanalyse von "Der Aktionär":
Michel Doepke vom Anlegermagazin "Der Aktionär" nimmt die Aktie von AbbVie Inc. (ISIN: US00287Y1091,…
Johnson & Johnson, Pfizer, Roche, AbbVie and Sanofi are included in this Analyst Blog.…
Heres what could happen next to AbbVie shares.…
Todays Research Daily features new research reports on 16 major stocks, including AbbVie Inc. (ABBV), Automatic Data Processing, Inc. (ADP)…
…
AbbVie cuts 2024 profit forecast on R&D expenses…
…
…
…
…
Wenig Kursbewegung aktuell bei der Aktie von AbbVie . Der jüngste Kurs betrug 196,85 US-Dollar. Kaum verändert im Vergleich zu…
Data from a late-stage study shows that AbbVies tavapadon reduced the burden of Parkinsons disease. The drug previously demonstrated efficacy…
AbbVies Parkinsons Disease drug meets main goal in late-stage trial…
IRW-PRESS: ACCESSWIRE News Network : Ripple Therapeutics kündigt Kooperations- und Lizenzoptionsvereinbarung mit AbbVie zur Entwicklung von innovativen Therapien für das…
Despite favorable views on litifilimab, AbbVie’s Rinvoq and BMS’ Sotyktu capture the most prescriber interest for approval, according to Spherix…
Visa, AbbVie, Anheuser-Busch, Servotronics and United-Guardian are included in this Analyst Blog.…
Todays Research Daily features new research reports on 16 major stocks, including Visa Inc. (V), AbbVie Inc. (ABBV) and Anheuser-Busch…
The Global Hematologic Malignancies Market Size was Valued at USD 67.18 Billion in 2023 and the Worldwide Hematologic Malignancies Market…
The Global Diabetes Associated Ophthalmic Treatment Market Size was Valued at USD 29.75 Billion in 2023 and the Worldwide Diabetes…
…
Anzeige / WerbungDr. Lior Shatiel, CEO von NurExone Biologic, vergleicht auf der bevorstehenden "Bioprocess International Conference" in Boston die Ansätze…
Wien (www.aktiencheck.de) - AbbVie-Aktienanalyse von der Raiffeisen Bank International AG:
Raphael Schicho, Analyst der Raiffeisen Bank International AG (RBI), stuft die…
For UK consumer, medical and trade media only
· In final guidance published today, adults in England and Wales…
AbbVies (ABBV) Tepkinly gets conditional approval in the EU to treat third-line patients with relapsed or refractory follicular lymphoma as…
The major indexes (^DJI,^GSPC, ^IXIC) are holding onto last week’s gains ahead of Federal Reserve Chair Jerome Powell’s remarks at…
Alphabet, AbbVie, Qualcomm and Flanigans are part of the Zacks top Analyst Blog.…
This is what could happen next to AbbVie shares.…
Todays Research Daily features new research reports on 16 major stocks, including Alphabet Inc. (GOOGL), AbbVie Inc. (ABBV) and QUALCOMM…
Here we discuss three drugmakers, Eli Lilly and Company (LLY), Pfizer (PFE) and AbbVie (ABBV), following their increase in sales…
Warren Buffett, known as the Oracle of Omaha, is a highly successful American investor who manages his portfolio consistently, regardless…
Investors who own AbbVies (ABBV) stock may stay invested as the company has faced its biggest challenge, Humiras patent cliff,…
The Global Regenerative Medicine Market Size was Valued at USD 31.90 Billion in 2023 and the Worldwide Regenerative Medicine Market…
Dublin, July 29, 2024 (GLOBE NEWSWIRE) -- The "U.S. Menopause Market Size, Share & Trends Analysis Report by…
…
…
AstraZeneca (AZN), Sanofi (SNY) and AbbVie (ABBV) announce second-quarter results. Merck (MRK) and Pfizers (PFE) phase III studies achieve primary…
ABBV earnings call for the period ending June 30, 2024.…
Wien (www.aktiencheck.de) - AbbVie-Aktienanalyse von der Raiffeisen Bank International AG:
Raphael Schicho, Analyst der Raiffeisen Bank International AG (RBI), nimmt in…
AbbVie hikes full-year earnings guidance as Humira sales top estimates…
AbbVies (ABBV) second-quarter earnings and sales beat estimates. Management hikes the EPS guidance on encouraging product sales for immunology drugs.…
The big pharma companys top drug is losing ground, but its dividend keeps rising.…
The big pharma companys top drug is losing ground, but its dividend keeps rising.…
Investor focus will likely be on sales of AbbVies (ABBV) blockbuster immunology drugs Rinvoq and Skyrizi when it reports second-quarter…
…